Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Alto Neuroscience, Inc. (ANRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ANRO (1-star) is a SELL. SELL since 4 days. Profits (-24.91%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.33
1 Year Target Price $11.33
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -89.63% | Avg. Invested days 15 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.62M USD | Price to earnings Ratio - | 1Y Target Price 11.33 |
Price to earnings Ratio - | 1Y Target Price 11.33 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 1.60 - 17.55 | Updated Date 07/4/2025 |
52 Weeks Range 1.60 - 17.55 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.88% | Return on Equity (TTM) -38.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -70696497 | Price to Sales(TTM) - |
Enterprise Value -70696497 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 27072100 | Shares Floating 17903611 |
Shares Outstanding 27072100 | Shares Floating 17903611 | ||
Percent Insiders 7.48 | Percent Institutions 77.52 |
Upturn AI SWOT
Alto Neuroscience, Inc.
Company Overview
History and Background
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized medicines for mental health. Founded in 2019, it leverages its platform to identify brain-based biomarkers to better match patients to treatments.
Core Business Areas
- Drug Development: Developing novel therapies targeting specific brain circuits and biomarkers associated with mental health conditions.
- Biomarker Platform: Utilizing its platform to identify and validate biomarkers that predict treatment response in mental health disorders.
- Personalized Medicine: Aiming to provide personalized treatment options based on individual patient characteristics and biomarker profiles.
Leadership and Structure
The leadership team includes Amit Etkin, MD, PhD (Founder and CEO), and other experienced executives in drug development and neuroscience. The company operates with a focus on research and development, clinical trials, and strategic partnerships.
Top Products and Market Share
Key Offerings
- ALTO-100: ALTO-100 is Alto's lead asset. It is being developed for major depressive disorder. Market share and revenue data are not yet available, as it is still in clinical trials. Competitors include companies developing other novel antidepressants and existing SSRIs and SNRIs.
- ALTO-202: ALTO-202 is being developed for post-traumatic stress disorder (PTSD). Market share and revenue data are not yet available, as it is still in clinical trials. Competitors include companies developing other PTSD treatments and existing therapies.
Market Dynamics
Industry Overview
The mental health therapeutics market is large and growing, driven by increasing prevalence of mental health disorders, greater awareness, and demand for more effective treatments.
Positioning
Alto Neuroscience, Inc. is positioning itself as a leader in personalized medicine for mental health by using its biomarker platform to identify patients most likely to respond to its therapies. This targeted approach aims to improve treatment outcomes and reduce trial and error in prescribing medications.
Total Addressable Market (TAM)
The global market for mental health therapeutics is estimated to be over $100 billion. Alto Neuroscience is positioned to capture a significant portion of this TAM by developing targeted therapies for specific patient populations.
Upturn SWOT Analysis
Strengths
- Novel biomarker platform
- Personalized medicine approach
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Early-stage company
- Reliance on clinical trial success
- High cash burn rate
- Limited commercial infrastructure
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new indications
- Advancements in biomarker technology
- Increased adoption of personalized medicine
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- VRTX
- GRTX
Competitive Landscape
Alto Neuroscience, Inc. differentiates itself through its personalized medicine approach and biomarker platform. It faces competition from larger pharmaceutical companies with established products and pipelines.
Growth Trajectory and Initiatives
Historical Growth: Not applicable.
Future Projections: Future growth depends on the success of its clinical trials and regulatory approvals. Analyst estimates are not publicly available at this time, since they are not public
Recent Initiatives: Recent initiatives include advancing its clinical programs, expanding its biomarker platform, and forging strategic collaborations.
Summary
Alto Neuroscience is an early-stage biopharmaceutical company with a promising personalized medicine approach to mental health. Its success depends on the clinical trial outcomes and it faces competition from larger, established companies. The biomarker platform and targeted therapies provide a competitive advantage, but the company needs to manage its cash burn and secure partnerships for long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Clinical Trial Data (Public)
- Third-Party Analytics
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Information is current as of the date of generation and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alto Neuroscience, Inc.
Exchange NYSE | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2024-02-02 | Founder, Chairman of the Board, CEO & President Dr. Amit Etkin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://www.altoneuroscience.com |
Full time employees 76 | Website https://www.altoneuroscience.com | ||
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.